The therapeutic window of antibody drug conjugates: A dogma in need of revision
- PMID: 36240779
- DOI: 10.1016/j.ccell.2022.09.016
The therapeutic window of antibody drug conjugates: A dogma in need of revision
Abstract
Despite a prevailing dogma wherein antibody drug conjugates (ADCs) increase the maximum tolerated dose of potent cytotoxin payloads while lowering the minimum effective dose, mounting clinical evidence argues that the tolerated doses of ADCs are not significantly different from those of related small molecules. Nonetheless, when dosed at or near the maximum tolerated dose, certain ADCs demonstrate improved efficacy. Understanding the challenges and opportunities for this class of biotherapeutics will help improve the design of next-generation ADCs.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests R.C. and J.R.R. are employees and shareholders of Zymeworks Inc. and work to develop antibody drug conjugates for therapeutic applications.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
